4-TCPA is a potent inhibitor of VEGFR2. It induces apoptosis and causes cell cycle arrest, potentially by inhibiting VEGFR2 and EGFR signaling, while also affecting the mTOR pathway. Furthermore, 4-TCPA suppresses the viability and proliferation of various cancer cell lines. It is applicable in research on cancers such as lung cancer, breast cancer, and leukemia.

4-TCPA exhibits varying IC50 values across different cell lines when tested for 72 hours, with an IC50 of 35.70 μM in A549 cells, 19.50 μM in MCF7 cells, 5.95 μM in K562 cells, and 135.2 μM in HFF2 cells. Within the 5.95-35.70 μM range over 72 hours, 4-TCPA induces apoptosis by activating the mitochondrial pathway in the K562, MCF7, and A549 cell lines, demonstrating different levels of sensitivity.